Go Pro
NASDAQ:OMCL

Omnicell (OMCL) Stock Price, News & Analysis

Omnicell logo
$33.03 +0.04 (+0.12%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$32.83 -0.20 (-0.62%)
As of 07:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Omnicell Stock (NASDAQ:OMCL)

Advanced

Key Stats

Today's Range
$32.60
▼
$33.23
50-Day Range
$32.23
▼
$45.87
52-Week Range
$29.06
▼
$55.00
Volume
499,229 shs
Average Volume
573,784 shs
Market Capitalization
$1.50 billion
P/E Ratio
39.32
Dividend Yield
N/A
Price Target
$57.86
Consensus Rating
Moderate Buy

Company Overview

Omnicell, Inc. is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum. The company completed its initial public offering on the Nasdaq under the ticker OMCL and has invested heavily in research and development, focusing on robotics, bar-coding and cloud-based data services. Omnicell’s continuous product enhancements reflect its commitment to automating complex pharmacy processes and driving digital transformation in healthcare.

Omnicell serves a global customer base that includes acute care hospitals, health systems, retail pharmacies and long-term care facilities. While its primary market remains North America, the company maintains operations and support centers throughout Europe and the Asia-Pacific region. This international footprint enables Omnicell to tailor solutions to diverse regulatory environments and to partner with healthcare organizations worldwide in improving medication safety and operational efficiency.

Under the leadership of co-founder and Chief Executive Officer Randall A. Lipps, Omnicell has expanded its technology suite to address emerging needs such as antimicrobial stewardship, telepharmacy and remote drug distribution. The company’s executive team continues to prioritize innovation, seeking to integrate advanced analytics and artificial intelligence into its platforms to help clinicians make more informed decisions and enhance overall patient care.

AI Generated. May Contain Errors.

Omnicell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

OMCL MarketRank™: 

Omnicell scored higher than 79% of companies evaluated by MarketBeat, and ranked 119th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Omnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Omnicell has a consensus price target of $57.86, representing about 75.2% upside from its current price of $33.03.

  • Amount of Analyst Coverage

    Omnicell has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Omnicell's stock forecast and price target.
  • Earnings Growth

    Earnings for Omnicell are expected to decrease by -26.95% in the coming year, from $1.41 to $1.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Omnicell is 39.32, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.92.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Omnicell is 39.32, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.39.

  • Price to Earnings Growth Ratio

    Omnicell has a PEG Ratio of 0.83. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Omnicell has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Omnicell's valuation and earnings.
  • Percentage of Shares Shorted

    7.45% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 5.48.
  • Change versus previous month

    Short interest in Omnicell has recently decreased by 0.08%, indicating that investor sentiment is improving.
  • Dividend Yield

    Omnicell does not currently pay a dividend.

  • Dividend Growth

    Omnicell does not have a long track record of dividend growth.

  • News Sentiment

    Omnicell has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Omnicell this week, compared to 4 articles on an average week.
  • Search Interest

    4 people have searched for OMCL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Omnicell to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Omnicell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.92% of the stock of Omnicell is held by insiders.

  • Percentage Held by Institutions

    97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Omnicell's insider trading history.
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OMCL Stock News Headlines

Omnicell (OMCL) Stock Trades Below Fair Value After A 78% Slump
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Headlines

OMCL Stock Analysis - Frequently Asked Questions

Omnicell's stock was trading at $45.30 at the beginning of 2026. Since then, OMCL stock has decreased by 27.1% and is now trading at $33.03.

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Thursday, July, 30th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.47. The business's revenue for the quarter was up 7.4% on a year-over-year basis.
Read the conference call transcript
.

Omnicell subsidiaries include MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and more.

Omnicell's top institutional shareholders include BlackRock Inc. (16.58%), Wellington Management Group LLP (5.94%), First Light Asset Management LLC (0.99%) and Legal & General Group Plc (0.38%). Insiders that own company stock include Nnamdi Njoku, Corey J Manley and Mark W Parrish.
View institutional ownership trends
.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
7/30/2026
Today
9/25/2026
Next Earnings (Estimated)
10/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:OMCL
CIK
926326
Employees
3,580
Year Founded
1992

Price Target and Rating

High Price Target
$70.00
Low Price Target
$45.00
Potential Upside/Downside
+75.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.84
Trailing P/E Ratio
39.32
Forward P/E Ratio
23.43
P/E Growth
0.83
Net Income
$2.05 million
Net Margins
3.13%
Pretax Margin
4.90%
Return on Equity
5.66%
Return on Assets
3.57%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
1.64
Quick Ratio
1.43

Sales & Book Value

Annual Sales
$1.18 billion
Price / Sales
1.27
Cash Flow
$2.75 per share
Price / Cash Flow
11.99
Book Value
$27.45 per share
Price / Book
1.20

Miscellaneous

Outstanding Shares
45,480,000
Free Float
44,151,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.97

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:OMCL) was last updated on 9/25/2026 by MarketBeat.com Staff.
From Our Partners